Form 4: Cargo Therapeutics CEO Gina Chapman Reports Acquisition of 200,000 Shares of Common Stock
SEC Form 4
Gina Chapman, President & CEO of Cargo Therapeutics, reports acquiring 200,000 shares of common stock and disposing of 303,905 shares.
Summary
- This is a Form 4 filing indicating changes in beneficial ownership of Cargo Therapeutics, Inc. [CRGX] stock by Gina Chapman, the President & CEO.
- On March 14, 2025, Ms. Chapman acquired 200,000 shares of Common Stock.
- Ms. Chapman also disposed of 303,905 shares of Common Stock on the same date.
- Following these transactions, Ms. Chapman directly owns 303,905 shares of Common Stock.
- The acquired shares are in the form of restricted stock units (RSUs) that vest quarterly, starting January 1, 2025, with full vesting occurring on the fourth anniversary.
Sentiment
Score: 5
Explanation: The document presents a neutral view of insider trading activity. The acquisition of shares is potentially positive, while the disposal of shares is potentially negative. The overall impact is unclear without further context.
Positives
- The acquisition of 200,000 shares by the CEO could be interpreted as a positive signal, indicating confidence in the company's future prospects.
Negatives
- The disposal of 303,905 shares by the CEO could be interpreted as a negative signal.
Risks
- The vesting schedule of the RSUs could influence the CEO's decisions regarding the company's long-term strategy.
- The disposal of 303,905 shares by the CEO could indicate a lack of confidence in the company's future prospects.
Future Outlook
The vesting schedule of the RSUs extends over four years, suggesting a long-term commitment from the CEO.
Industry Context
Form 4 filings are a standard part of regulatory compliance for publicly traded companies, providing transparency into the trading activities of company insiders.
Stakeholder Impact
- Shareholders may react to the CEO's stock transactions, potentially influencing the stock price.
- Employees may view the CEO's stock transactions as a signal of confidence or concern about the company's future.
Key Dates
| Date | Description |
|---|---|
| January 1, 2025 | Vesting Commencement Date for the restricted stock units. |
| March 14, 2025 | Date of the reported transaction: acquisition of 200,000 shares and disposal of 303,905 shares. |
| March 18, 2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.